For example, compared with participants in the median quantile (45%–55%) of the risk score, those in the highest 5% had a more than 14-, 19- and a 5-fold increase in the relative risk of developing IDH mutant and 1p/19q codeleted, IDH mutant and 1p/19q non-codeleted, and IDH wild-type glioma, respectively. This evidence concerns the gene IDH1 and central nervous system cancer.